Effect of Pitavastatin on Coronary Flow Reserve in Hypertensive Patients (EPOCH)
Primary Purpose
Hypertension, Cardiovascular Risk
Status
Completed
Phase
Phase 4
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Pitavastatin
Control
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension focused on measuring Hypertension, Statin
Eligibility Criteria
Inclusion Criteria:
- Controlled Hypertension: treated SBP<140 mmHg and DBP<90 mmHg
- LDL cholesterol ≥ 130mg/dL
- Patients with statin-naive state, defined as receiving no statin therapy for more than 6 months during the previous 12 months.
- Any 1 of these cardiovascular risk factors required: smoking, age over 55 (men) or 65 (women), history of cerebrovascular event, family history of early CHD before age 55, HDL cholesterol < 40 mg/dL
Exclusion Criteria:
- A previous history of intolerance or hypersensitivity to statins
- Uncontrolled hypertension; SBP≥140 mmHg or DBP≥90 mmHg
- Previous MI or currently treated angina pectoris
- Stroke, TIA < 3 months
- Secondary hypertension
- Fasting serum triglyceride > 500 mg/dL
- Clinical congestive heart failure
- Uncontrolled arrhythmia
- Left ventricular hypertrophy: LV mass index >134g/m2 (male) or >110g/m2 (female)
- Concomitant clinically important hematological, gastrointestinal, hepatic, renal or other disease
- Pregnant or lactating women and those of child-bearing potential
- Diabetes
- Peripheral vascular disease
- Unwillingness or inability to comply with the procedures described in this protocol
Sites / Locations
- Asan Medical Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Active Comparator
Arm Label
Control
Pitavastatin
Arm Description
Patients continue taking their antihypertensive medication alone.
Pitavastatin 4 mg is given to study patients after a baseline assessment and continued for 1 year without further dose titration. Patients continue taking their antihypertensive medication during the entire follow-up period.
Outcomes
Primary Outcome Measures
change in the CFR value
Change of coronary flow velocity reserve from baseline to 1 year follow-up. For each patient, the averaged value of coronary flow velocity reserve will be obtained at baseline and 1 year follow-up.
Difference in mean CFR value
DIfference in CFR value at 12 month follow-up between pitavastatin and placebo arm
Secondary Outcome Measures
change of CRP
Change of CRP from baseline to 1 year follow-up.
Change of LDL-cholesterol
Change of LDL-cholesterol from baseline to 1 year follow-up.
Change of averaged peak diastolic velocity
Change of averaged peak diastolic velocity from baseline to study end.
Full Information
NCT ID
NCT02144922
First Posted
May 20, 2014
Last Updated
October 13, 2016
Sponsor
Asan Medical Center
Collaborators
JW Pharmaceutical
1. Study Identification
Unique Protocol Identification Number
NCT02144922
Brief Title
Effect of Pitavastatin on Coronary Flow Reserve in Hypertensive Patients
Acronym
EPOCH
Official Title
Effect of Pitavastatin on Coronary Flow Reserve in Hypertensive Patients With Cardiovascular Risk
Study Type
Interventional
2. Study Status
Record Verification Date
October 2016
Overall Recruitment Status
Completed
Study Start Date
May 2014 (undefined)
Primary Completion Date
October 2016 (Actual)
Study Completion Date
October 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Asan Medical Center
Collaborators
JW Pharmaceutical
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Although statins reduce cardiac events in hypertensive patients with cardiovascular risk factors, the effect of statins on coronary flow reserve (CFR) has not been examined in such patients. The investigators hypothesize that pitavastatin added to standard antihypertensive therapy will be superior to placebo in improving CFR in hypertensive patients with cardiovascular risk, and try to examine this hypothesis in a double-blind, randomized comparison study using Doppler echocardiography.
Detailed Description
Statin treatment improves coronary flow reserve (CFR) and decreases cardiac morbidity and mortality in patients with coronary artery disease (CAD) and hypercholesterolemia. Endothelial dysfunction and impairment in coronary microcirculation is also observed in hypertensive patients with cardiovascular risk factors. However, the measurement of CFR has rarely been performed in hypertensive patients without CAD, because CFR could be invasively measured using a Doppler guide wire in a cardiac catheterization laboratory. Recent advances in echocardiographic imaging techniques have made it possible to measure coronary flow velocity and CFR, which highly correlates with the CFR measured by invasive means.
Lipid lowering with a statin provided beneficial effects in patients with average levels of serum total cholesterol in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA) study conducted in hypertensive patients at cardiovascular risk. Improvements in endothelial dysfunction and CFR may be related to the beneficial effects of statins in hypertensive patients without hypercholesterolemia, but the effect of statins on CFR has not been examined in such patients. Accordingly, the investigators try to examine the hypothesis that pitavastatin added to standard antihypertensive therapy in hypertensive patients with cardiovascular risk will be superior to placebo in improving CFR in a double-blind, randomized comparison study using Doppler echocardiography.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension, Cardiovascular Risk
Keywords
Hypertension, Statin
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
85 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Control
Arm Type
Placebo Comparator
Arm Description
Patients continue taking their antihypertensive medication alone.
Arm Title
Pitavastatin
Arm Type
Active Comparator
Arm Description
Pitavastatin 4 mg is given to study patients after a baseline assessment and continued for 1 year without further dose titration. Patients continue taking their antihypertensive medication during the entire follow-up period.
Intervention Type
Drug
Intervention Name(s)
Pitavastatin
Other Intervention Name(s)
Livalo
Intervention Description
statin
Intervention Type
Other
Intervention Name(s)
Control
Intervention Description
Life style modification alone
Primary Outcome Measure Information:
Title
change in the CFR value
Description
Change of coronary flow velocity reserve from baseline to 1 year follow-up. For each patient, the averaged value of coronary flow velocity reserve will be obtained at baseline and 1 year follow-up.
Time Frame
12 months
Title
Difference in mean CFR value
Description
DIfference in CFR value at 12 month follow-up between pitavastatin and placebo arm
Time Frame
12 months
Secondary Outcome Measure Information:
Title
change of CRP
Description
Change of CRP from baseline to 1 year follow-up.
Time Frame
12 months
Title
Change of LDL-cholesterol
Description
Change of LDL-cholesterol from baseline to 1 year follow-up.
Time Frame
12 months
Title
Change of averaged peak diastolic velocity
Description
Change of averaged peak diastolic velocity from baseline to study end.
Time Frame
12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
35 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Controlled Hypertension: treated SBP<140 mmHg and DBP<90 mmHg
LDL cholesterol ≥ 130mg/dL
Patients with statin-naive state, defined as receiving no statin therapy for more than 6 months during the previous 12 months.
Any 1 of these cardiovascular risk factors required: smoking, age over 55 (men) or 65 (women), history of cerebrovascular event, family history of early CHD before age 55, HDL cholesterol < 40 mg/dL
Exclusion Criteria:
A previous history of intolerance or hypersensitivity to statins
Uncontrolled hypertension; SBP≥140 mmHg or DBP≥90 mmHg
Previous MI or currently treated angina pectoris
Stroke, TIA < 3 months
Secondary hypertension
Fasting serum triglyceride > 500 mg/dL
Clinical congestive heart failure
Uncontrolled arrhythmia
Left ventricular hypertrophy: LV mass index >134g/m2 (male) or >110g/m2 (female)
Concomitant clinically important hematological, gastrointestinal, hepatic, renal or other disease
Pregnant or lactating women and those of child-bearing potential
Diabetes
Peripheral vascular disease
Unwillingness or inability to comply with the procedures described in this protocol
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Duk-Hyun Kang, M.D.
Organizational Affiliation
Asan Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Asan Medical Center
City
Seoul
ZIP/Postal Code
138-736
Country
Korea, Republic of
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Effect of Pitavastatin on Coronary Flow Reserve in Hypertensive Patients
We'll reach out to this number within 24 hrs